Laurion Capital Management’s Pacira BioSciences PCRX Stock Holding History

Laurion Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-22,300	Closed	-$1.01M	–	1005
2019 Q4	$1.01M	Buy	+22,300	New	+$947K	0.01%	570
2019 Q3	–	Sell	-13,001	Closed	-$565K	–	1210
2019 Q2	$565K	Sell	13,001 -32,339	-71%	-$1.37M	0.01%	677
2019 Q1	$1.73M	Buy	+45,340	New	+$1.77M	0.02%	406
2018 Q2	–	Sell	-96,126	Closed	-$2.99M	–	1521
2018 Q1	$2.99M	Buy	+96,126	New	+$3.42M	0.02%	512
2015 Q2	–	Sell	-4,464	Closed	-$397K	–	678
2015 Q1	$397K	Buy	+4,464	New	+$453K	0.01%	268

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Laurion Capital Management's PCRX Position: Q1 2020 in Review

Laurion Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2020, closing a stake of 22,300 shares — an estimated $1.01M sold.

Laurion Capital Management first reported a position in PCRX in Q1 2015 and held it in 5 quarters. The position peaked at $2.99M in Q1 2018. 226 funds tracked by Wall St. Rank hold PCRX as of Q1 2020.

Laurion Capital Management reported no remaining Pacira BioSciences position as of Q1 2020 after selling out during the quarter.
Laurion Capital Management sold 22,300 Pacira BioSciences shares in Q1 2020, an estimated $1.01M.
Laurion Capital Management first reported a position in Pacira BioSciences in Q1 2015 and held it in 5 quarters.
Laurion Capital Management's Pacira BioSciences position peaked at $2.99M in Q1 2018.
226 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2020.

Based on Laurion Capital Management's 13F filing for Q1 2020, filed 14 May 2020.